Quince Therapeutics Inc

Overview

1. "How the company got here" - Quince Therapeutics, Inc. was originally incorporated in 2012 and was formerly known as Cortexyme, Inc. The company underwent a significant transformation, including a name change to Quince Therapeutics in August 2022, to reflect a strategic shift towards developing therapies for rare and debilitating diseases. This repositioning involved acquiring assets and companies, such as EryDel S.p.A. and Orphai Therapeutics, to focus on specific clinical-stage programs. The company has experienced significant volatility, including a substantial stock price drop following the failure of a late-stage clinical trial for its lead asset in treating ataxia-telangiectasia. More recently, in October 2026, the company rebranded to IRulya Therapeutics, Inc. and changed its stock ticker to IRLA, signaling a renewed focus on its pulmonary disease program. 2. "What it actually does" - Quince Therapeutics, now operating as IRulya Therapeutics, is a biotechnology company focused on developing treatments for rare diseases. Their core approach involves leveraging a patient's own biology to create innovative therapies. A key technology platform they utilize is called Autologous Intracellular Drug Encapsulation (AIDE), which involves encapsulating drugs within a patient's own red blood cells. This method aims to improve drug delivery, enhance tolerability, and potentially reduce side effects compared to traditional drug administration. The company's pipeline has evolved over time, with a current emphasis on specific rare conditions. 3. "LAM-001 (Pulmonary Diseases)" - This business line focuses on developing LAM-001, an inhaled rapamycin formulation. LAM-001 is being investigated for rare pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS) after lung transplants. The company is conducting various clinical trials, including Phase 2 studies, to evaluate the safety and efficacy of LAM-001. This segment represents a significant strategic focus for the company following recent acquisitions and rebranding efforts. 4. "eDSP (Neurological Rare Diseases)" - This business line centers on eDSP (encapsulated dexamethasone sodium phosphate), a drug developed using the AIDE technology platform. eDSP is designed to treat rare neurological disorders, with a primary focus on ataxia-telangiectasia (A-T), a rare pediatric neurodegenerative disease. The AIDE platform encapsulates the corticosteroid dexamethasone into a patient's red blood cells to potentially provide sustained release and reduce the side effects commonly associated with long-term corticosteroid use. The company has conducted Phase 3 clinical trials for eDSP in A-T patients. 5. "NOV004 (Skeletal and Bone Disorders)" - This business line involves the development of NOV004, a bone-targeting drug platform. NOV004 is an anabolic peptide designed to concentrate at fracture sites to promote bone repair and regeneration. Preclinical studies have indicated that NOV004 can accelerate fracture healing, improving bone density and strength. This program was a key focus for the company after its rebranding to Quince Therapeutics in 2022, aiming to address unmet needs in skeletal and bone disorders. 6. "What management is betting on now" - Management is currently focused on advancing the clinical development of LAM-001 for pulmonary diseases, which has become a primary strategic priority after recent corporate changes and acquisitions. They are also continuing development of eDSP for rare neurological diseases, despite past clinical trial setbacks. The company is actively seeking to extend its cash runway, with current cash expected to fund operations through 2028, and is exploring strategic alternatives to maximize shareholder value. Recent analyst coverage has been largely positive, with several firms initiating or reiterating "Outperform" or "Buy" ratings, citing the potential of their drug candidates.1. "How the company got here" - Quince Therapeutics, Inc. was originally incorporated in 2012 and was formerly known as Cortexyme, Inc. The company underwent a significant transformation, including a name change to Quince Therapeutics in August 2022, to reflect a strategic shift towards developing therapies for rare and debilitating diseases. This repositioning involved acquiring assets and companies, such as EryDel S.p.A. and Orphai Therapeutics, to focus on specific clinical-stage programs. The company has experienced significant volatility, including a substantial stock price drop following the failure of a late-stage clinical trial for its lead asset in treating ataxia-telangiectasia. More recently, in October 2026, the company rebranded to IRulya Therapeutics, Inc. and changed its stock ticker to IRLA, signaling a renewed focus on its pulmonary disease program. 2. "What it actually does" - Quince Therapeutics, now operating as IRulya Therapeutics, is a biotechnology company focused on developing treatments for rare diseases. Their core approach involves leveraging a patient's own biology to create innovative therapies. A key technology platform they utilize is called Autologous Intracellular Drug Encapsulation (AIDE), which involves encapsulating drugs within a patient's own red blood cells. This method aims to improve drug delivery, enhance tolerability, and potentially reduce side effects compared to traditional drug administration. The company's pipeline has evolved over time, with a current emphasis on specific rare conditions. 3. "LAM-001 (Pulmonary Diseases)" - This business line focuses on developing LAM-001, an inhaled rapamycin formulation. LAM-001 is being investigated for rare pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS) after lung transplants. The company is conducting various clinical trials, including Phase 2 studies, to evaluate the safety and efficacy of LAM-001. This segment represents a significant strategic focus for the company following recent acquisitions and rebranding efforts. 4. "eDSP (Neurological Rare Diseases)" - This business line centers on eDSP (encapsulated dexamethasone sodium phosphate), a drug developed using the AIDE technology platform. eDSP is designed to treat rare neurological disorders, with a primary focus on ataxia-telangiectasia (A-T), a rare pediatric neurodegenerative disease. The AIDE platform encapsulates the corticosteroid dexamethasone into a patient's red blood cells to potentially provide sustained release and reduce the side effects commonly associated with long-term corticosteroid use. The company has conducted Phase 3 clinical trials for eDSP in A-T patients. 5. "NOV004 (Skeletal and Bone Disorders)" - This business line involves the development of NOV004, a bone-targeting drug platform. NOV004 is an anabolic peptide designed to concentrate at fracture sites to promote bone repair and regeneration. Preclinical studies have indicated that NOV004 can accelerate fracture healing, improving bone density and strength. This program was a key focus for the company after its rebranding to Quince Therapeutics in 2022, aiming to address unmet needs in skeletal and bone disorders. 6. "What management is betting on now" - Management is currently focused on advancing the clinical development of LAM-001 for pulmonary diseases, which has become a primary strategic priority after recent corporate changes and acquisitions. They are also continuing development of eDSP for rare neurological diseases, despite past clinical trial setbacks. The company is actively seeking to extend its cash runway, with current cash expected to fund operations through 2028, and is exploring strategic alternatives to maximize shareholder value. Recent analyst coverage has been largely positive, with several firms initiating or reiterating "Outperform" or "Buy" ratings, citing the potential of their drug candidates.